2021
The ongoing clinical phase I/II trial with FG001 is designed as a two-phased trial, where the first phase aims to identify the optimal...
Summary *) Result per share (DKK per share): Operating result divided by the average number of shares during the period. The total...
Earlier this year the Company announced it had acquired worldwide exclusive rights to use FG001 for photothermal therapy. Now the first...
20 August, 2021
FluoGuide receives tranche of EUR 750,000 under its ongoing grant from EIC Accelerator - SME Instrument under European Union for FG001
Last year, the Company announced it was awarded with a grant on in total EUR 2.5 million under the European Innovation Council (EIC)...
FG001 was well tolerated, and light was detected in all patients at the fifth dose level (16mg) administered in the evening before...
The ongoing clinical phase I/II trial with FG001 is designed as a two-phase trial, where the first phase aims to identify the optimal...
30 June, 2021
FluoGuide enters agreement with Swedish university hospital for the second phase of the ongoing FG001 clinical trial
The ongoing clinical phase I/II trial with FG001 is designed as a two-phase trial, where the first phase aims to identify the optimal...
The agenda for the general meeting was as follows: Following was decided on the extraordinary General Meeting: Re 1: Election of...
17 June, 2021
New article reveals promising results of using FluoGuide’s FG002 technology in guiding surgical removal of cancer
The preclinical study demonstrated FG002 to light up cancer with several promising features holding great promises for the use of guiding...